European regulators have recommended expanding Maviret, a dual direct-acting antiviral, to include acute hepatitis C infection in adults and children.
C-FORWARD is the Second Phase 3 Trial in the Global HCV Development Program; the First Phase 3 Trial, C-BEYOND, is Currently Enrolling Patients in the US and Canada Regimen has Potential Best-in-Class ...
On Tuesday, Cherokee Nation Principal Chief Chuck Hoskin Jr. signed a proclamation designating May as Hepatitis C Awareness ...
Atea Pharmaceuticals announced the ongoing enrollment in its Phase 3 C-BEYOND trial evaluating the combination of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV). Positive ...
“Nevertheless, these findings highlight the importance of treatment adherence, regular follow-up, and targeted prevention in order to reach the WHO [World Health Organization] HCV elimination goals,” ...
Injection drug use is both a potent risk factor for incarceration and the primary transmission route for hepatitis C virus (HCV) infections. Combining HCV testing and treatment in jails with ...
MANCHESTER and LONDON, England — Alison Starkie spends her days tracking down people who need testing or treatment for hepatitis C, especially those who are unhoused or actively using drugs. Starkie, ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Annual courses of direct-acting antivirals for HCV have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results